Exosomal Immune Checkpoint Molecules as Liquid Biopsy Markers
DOI:
https://doi.org/10.32628/IJSRST25126423Keywords:
Exosomes, Liquid biopsy, Immune checkpoint molecules, Exosomal PD-L1, Cancer immunotherapy, Precision oncologyAbstract
Immune checkpoint inhibitors have revolutionized the management of cancer; unfortunately, there are few stable and least invasive biomarkers in forecasts and monitoring of therapeutic response. Traditional tissue biopsies do have limitations in the heterogeneity of tumors, invasiveness of the procedure and a limited temporal model. Liquid biopsy is therefore an emerging alternative and increasing evidence is presenting the tumor-derived exosomes as information-rich circulating biomarkers. Exosomes are directly engaged in tumorimmune crosstalk capable of carrying immune checkpoint molecules, programmed death-ligand 1 (PD-L1), programmed death-1 (PD-1), and other co-inhibitory controls, and is involved in immune escape and therapy resistance. Recent publications also show that exosomal immune checkpoint molecules can not only indicate the dynamism of the immune status of the tumor microenvironment, but also offer better stability and sensitivity than soluble or cell-based biomarkers. This review critically analyses the biological and clinical usefulness and technological improvements connected with exosomal immune checkpoint molecules as markers in liquid biopsy. We address their diagnostic, prognostic and predictive value in a variety of types of cancer, and we pay special attention to the immunotherapy response assay. Existing problems, such as analytical standardization, biological heterogeneity, and clinical validation are also dealt with. Lastly, prospective outlooks into incorporating exosomal immune checkpoint profiling in precision immuno-oncology are discussed highlighting its capacity to direct personalized cancer immunotherapy.
Downloads
References
Akbar, S., Raza, A., Mohsin, R., Kanbour, A., Qadri, S., Parray, A., ... & Dermime, S. (2023). Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients. Frontiers in Immunology, 13, 1097117. https://doi.org/10.3389/fimmu.2022.1097117 DOI: https://doi.org/10.3389/fimmu.2022.1097117
An, H. J., Chon, H. J., & Kim, C. (2021). Peripheral blood-based biomarkers for immune checkpoint inhibitors. International journal of molecular sciences, 22(17), 9414. https://doi.org/10.3390/ijms22179414 DOI: https://doi.org/10.3390/ijms22179414
Fatima, S., Ma, Y., Safrachi, A., Haider, S., Spring, K. J., Vafaee, F., ... & de Souza, P. (2022). Harnessing liquid biopsies to guide immune checkpoint inhibitor therapy. Cancers, 14(7), 1669. https://doi.org/10.3390/cancers14071669 DOI: https://doi.org/10.3390/cancers14071669
Yu, D., Li, Y., Wang, M., Gu, J., Xu, W., Cai, H., ... & Zhang, X. (2022). Exosomes as a new frontier of cancer liquid biopsy. Molecular cancer, 21(1), 56. https://doi.org/10.1186/s12943-022-01509-9 DOI: https://doi.org/10.1186/s12943-022-01509-9
Gunasekaran, M., Russo, A., Cardona, A. F., de Miguel Perez, D., Lapidus, R., Cooper, B., ... & Rolfo, C. (2020). Exosomal PD-L1 expression as non-invasive biomarker for immune checkpoint inhibitors in non-small cell lung cancer. The Journal of Immunology, 204(1_Supplement), 90-10. https://doi.org/10.4049/jimmunol.204.Supp.90.10 DOI: https://doi.org/10.4049/jimmunol.204.Supp.90.10
Yang, W. Y., Feng, L. F., Meng, X., Chen, R., Xu, W. H., Hou, J., ... & Zhang, L. (2020). Liquid biopsy in head and neck squamous cell carcinoma: circulating tumor cells, circulating tumor DNA, and exosomes. Expert Review of Molecular Diagnostics, 20(12), 1213-1227. https://doi.org/10.1080/14737159.2020.1855977 DOI: https://doi.org/10.1080/14737159.2020.1855977
Preethi, K. A., Selvakumar, S. C., Ross, K., Jayaraman, S., Tusubira, D., & Sekar, D. (2022). Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer. Molecular Cancer, 21(1), 54. https://doi.org/10.1186/s12943-022-01525-9 DOI: https://doi.org/10.1186/s12943-022-01525-9
Hu, C., Jiang, W., Lv, M., Fan, S., Lu, Y., Wu, Q., & Pi, J. (2022). Potentiality of exosomal proteins as novel cancer biomarkers for liquid biopsy. Frontiers in Immunology, 13, 792046. https://doi.org/10.3389/fimmu.2022.792046 DOI: https://doi.org/10.3389/fimmu.2022.792046
Asleh, K., Dery, V., Taylor, C., Davey, M., Djeungoue-Petga, M. A., & Ouellette, R. J. (2023). Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology. Biomarker research, 11(1), 99. https://doi.org/10.1186/s40364-023-00540-2 DOI: https://doi.org/10.1186/s40364-023-00540-2
Augustus, E., Zwaenepoel, K., Siozopoulou, V., Raskin, J., Jordaens, S., Baggerman, G., ... & Pauwels, P. (2021). Prognostic and predictive biomarkers in non-small cell lung cancer patients on immunotherapy—the role of liquid biopsy in unraveling the puzzle. Cancers, 13(7), 1675. https://doi.org/10.3390/cancers13071675 DOI: https://doi.org/10.3390/cancers13071675
Alotaibi, F. (2023). Exosomal microRNAs in cancer: potential biomarkers and immunotherapeutic targets for immune checkpoint molecules. Frontiers in Genetics, 14, 1052731. https://doi.org/10.3389/fgene.2023.1052731 DOI: https://doi.org/10.3389/fgene.2023.1052731
Sharma, A., & Johnson, A. (2020). Exosome DNA: Critical regulator of tumor immunity and a diagnostic biomarker. Journal of cellular physiology, 235(3), 1921-1932. https://doi.org/10.1002/jcp.29153 DOI: https://doi.org/10.1002/jcp.29153
Soda, N., Clack, K., & Shiddiky, M. J. (2022). Recent advances in liquid biopsy technologies for cancer biomarker detection. Sensors & Diagnostics, 1(3), 343-375. https://doi.org/10.1039/D2SD00010E DOI: https://doi.org/10.1039/D2SD00010E
Keup, C., Kimmig, R., & Kasimir-Bauer, S. (2020). Liquid biopsies to evaluate immunogenicity of gynecological/breast tumors: on the way to blood-based biomarkers for immunotherapies. Breast Care, 15(5), 470-480. https://doi.org/10.1159/000510509 DOI: https://doi.org/10.1159/000510509
Mummareddy, S., Pradhan, S., Narasimhan, A. K., & Natarajan, A. (2021). On demand biosensors for early diagnosis of cancer and immune checkpoints blockade therapy monitoring from liquid biopsy. Biosensors, 11(12), 500. https://doi.org/10.3390/bios11120500 DOI: https://doi.org/10.3390/bios11120500
Irmer, B., Chandrabalan, S., Maas, L., Bleckmann, A., & Menck, K. (2023). Extracellular vesicles in liquid biopsies as biomarkers for solid tumors. Cancers, 15(4), 1307. https://doi.org/10.3390/cancers15041307 DOI: https://doi.org/10.3390/cancers15041307
Yang, Q., Chen, M., Gu, J., Niu, K., Zhao, X., Zheng, L., ... & Sun, J. (2021). Novel biomarkers of dynamic blood PD-L1 expression for immune checkpoint inhibitors in advanced non-small-cell lung cancer patients. Frontiers in Immunology, 12, 665133. https://doi.org/10.3389/fimmu.2021.665133 DOI: https://doi.org/10.3389/fimmu.2021.665133
Lin, B., Lei, Y., Wang, J., Zhu, L., Wu, Y., Zhang, H., ... & Yang, C. (2021). Microfluidic‐based exosome analysis for liquid biopsy. Small methods, 5(3), 2001131. https://doi.org/10.1002/smtd.202001131 DOI: https://doi.org/10.1002/smtd.202001131
Zhang, Z., Wu, H., Chong, W., Shang, L., Jing, C., & Li, L. (2022). Liquid biopsy in gastric cancer: predictive and prognostic biomarkers. Cell death & disease, 13(10), 903. https://doi.org/10.1038/s41419-022-05350-2 DOI: https://doi.org/10.1038/s41419-022-05350-2
Liang, Y., Lehrich, B. M., Zheng, S., & Lu, M. (2021). Emerging methods in biomarker identification for extracellular vesicle‐based liquid biopsy. Journal of Extracellular Vesicles, 10(7), e12090. https://doi.org/10.1002/jev2.12090 DOI: https://doi.org/10.1002/jev2.12090
Yang, Y., Liu, H., Chen, Y., Xiao, N., Zheng, Z., Liu, H., & Wan, J. (2023). Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. Cell Death & Disease, 14(3), 230. https://doi.org/10.1038/s41419-023-05757-5 DOI: https://doi.org/10.1038/s41419-023-05757-5
Yang, J., Qiu, L., Wang, X., Chen, X., Cao, P., Yang, Z., & Wen, Q. (2023). Liquid biopsy biomarkers to guide immunotherapy in breast cancer. Frontiers in Immunology, 14, 1303491. https://doi.org/10.3389/fimmu.2023.1303491 DOI: https://doi.org/10.3389/fimmu.2023.1303491
Li, S., Yi, M., Dong, B., Tan, X., Luo, S., & Wu, K. (2021). The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. International journal of cancer, 148(11), 2640-2651. https://doi.org/10.1002/ijc.33386 DOI: https://doi.org/10.1002/ijc.33386
Downloads
Published
Issue
Section
License
Copyright (c) 2024 International Journal of Scientific Research in Science and Technology
This work is licensed under a Creative Commons Attribution 4.0 International License.
https://creativecommons.org/licenses/by/4.0
